Elinzanetant

依林奈坦

Report date: 2026/02/13 20:01:31
NMEFirst In Class

Base Information

Drug NameElinzanetant
Drug Alias NameLynkuetBAY-3427080BAY3427080NT-814GSK-1144814 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurokinin 1 receptor antagonistsNeurokinin 3 receptor antagonists
TargetsNeurokinin 1 receptorNeurokinin 3 receptor
Therapy Area/IndicationsVasomotor symptomHR-positive breast cancerMenopausal symptoms +[7] 
Global Approved IndicationsVasomotor symptomHot Flashes
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2025/07/10
Country/TerritoryCzechiaBelgiumBulgaria +[31] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesBayer AGBayer Healthcare Pharmaceuticals IncBayer Healthcare Company Ltd
Inactive CompaniesGlaxosmithkline PlcNerre Therapeutics LtdNew York State Psychiatric Institute
Active IndicationsVasomotor symptomHR-positive breast cancerMenopausal symptoms +[5] 
Inactive IndicationsSchizophreniaOpioid-Related Disorders

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG